SGLT2 Inhibition: Changing What Fuels the Heart

Affiliations

Free article

Editorial

Michael Lehrke. J Am Coll Cardiol. 2019.

Free article

. 2019 Apr 23;73(15):1945-1947.

doi: 10.1016/j.jacc.2019.02.023.

¹ Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany. Electronic address: mlehrke@ukaachen.de.

No abstract available

Keywords: SGLT2 inhibition; animal models; cardiac remodeling; diabetes; heart failure; myocardial metabolism.

Comment on

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, Flores E, Garcia-Ropero A, Sanz J, Hajjar RJ, Fuster V, Badimon JJ. Santos-Gallego CG, et al. J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056. J Am Coll Cardiol. 2019. PMID: 30999996